Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17975140 | 0.82 | CCR1 (0.37) | CCR1RAB9ACCR5MAPTALDH1A1 | |
| SCHEMBL29367157 | 0.79 | ENPP2 (0.32) | — | |
| SCHEMBL1506336 | 0.79 | ENPP2 (0.32) | — | |
| SCHEMBL29952243 | 0.77 | ENPP2 (0.31) | — | |
| SCHEMBL489376 | 0.76 | CCR1 (0.40) | CCR1RAB9ACCR5MAPTALDH1A1 | |
| SCHEMBL30788696 | 0.76 | CCR1 (0.40) | CCR1RAB9ACCR5MAPTALDH1A1 | |
| SCHEMBL20580799 | 0.76 | NOS2 (0.37) | RAB9AMAPTKDM4EKMT2AHTT | |
| SCHEMBL13260555 | 0.76 | ENPP2 (0.30) | — | |
| SCHEMBL29954275 | 0.74 | KDM4E (0.39) | CCR1RAB9ACCR5MAPTALDH1A1 | |
| SCHEMBL21156607 | 0.73 | NOS3 (0.38) | CCR1RAB9ACCR5MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4605397-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-120035594-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240217959-A1 | New (Homo)Piperidinyl Heterocycles as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-07-04 | — | — | US | disclosed |
| WO-2024086634-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| EP-2007750-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| US-7053079-B2 | Dihydroxy (3-pyridyl) borane compounds | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20040254076-A1 | Dihydroxy (3-pyridyl) borane compounds | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1460079-A1 | DIHYDROXY(3-PYRIDYL)BORANE COMPOUNDS | Koei Chemical Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ROS1, MCL1, ALK | CCR1 708/4885RAB9A 1675/4885CCR5 3763/4885 |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CCR1 2906/4885RAB9A 2168/4885CCR5 2319/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | CCR1 2906/4885RAB9A 2168/4885CCR5 2319/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CCR1 2906/4885RAB9A 2168/4885CCR5 2319/4885 |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | CCR1 4436/4885RAB9A 355/4885CCR5 4774/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | CCR1 2906/4885RAB9A 2168/4885CCR5 2319/4885 |
| US-20040254076-A1 | Dihydroxy (3-pyridyl) borane compounds | CYP24A1, DRD3, HSD3B1 | CCR1 394/4885RAB9A 445/4885CCR5 1733/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | CCR1 3506/4885RAB9A 2725/4885CCR5 1768/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CCR1 2906/4885RAB9A 2168/4885CCR5 2319/4885 |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | CCR1 1890/4885RAB9A 715/4885CCR5 334/4885 |
| US-20240217959-A1 | New (Homo)Piperidinyl Heterocycles as Sigma Ligands | SIGMAR1, TMEM97, OPRD1 | CCR1 1307/4885RAB9A 4270/4885CCR5 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.